The 3rd Annual RNAi – Based Therapeutics Summit Returns!
successfully develop targeted extrahepatic RNAi drugs
jenna.warren@hansonwade.com
Clinical, drug development, Life Science, pharma, RNAi
0 Comment
successfully develop targeted extrahepatic RNAi drugs
Phil Taylor
Dicerna, gene silencing, M&A, Novo Nordisk, RNAi
0 Comment
Phil Taylor
cholesterol, gene silencing, HEOR, inclisiran, Leqvio, market access, NHS, NICE, Novartis, RNAi
0 Comment
Phil Taylor
Diabetes, Dicerna, gene silencing, hepatology, NASH, Novo Nordisk, RNAi
0 Comment
Podcast/ R&D/ Views & Analysis/ Views and analysis
Dominic Tyer
Alnylam, coronavirus, COVID-19, gene silencing, podcast, RNAi
0 Comment
Richard Staines
Alnylam, Biotech, hepatology, Ionis, RNAi
0 Comment
Linda Banks
Alnylam, breakthrough Therapy, patisiran, rare disease, RNAi, Sanofi
0 Comment
Oncology/ Partner content/ Partner Content/ Press releases/ R&D
Pavan Solanki
cancer, dna, rna, RNAi, therapeutics
0 Comment
RNA Therapeutics 2018